Fig. 2.

CREG1 overexpression alleviated DOX-induced cardiotoxicity by inhibiting the myocardial ferroptosis

A-B. EF% and FS% in the Creg1-TG mice and WT mice after DOX treatment (n = 6 for the control group, n = 8 for the DOX group). C-D. HE staining, Masson’s trichrome staining, and WGA staining in the Creg1-TG mice and WT mice after DOX treatment (n = 3). E-F. Transmission electron microscope for mitochondria in the myocardium of Creg1-TG mice and WT mice after DOX treatment (n = 3). G-H. Western blotting of CREG1 and ferroptosis-related proteins in the Creg1-TG mice and WT mice after DOX treatment (n = 4). DOX: doxorubicin, Creg1-TG: Creg1 transgenic mice; WT mice: wild type mice. *p < 0.05, **p < 0.01 vs. WT mice; ^#p < 0.05, ^##p < 0.01 vs. Creg1-TG mice; ^&p < 0.05, ^&&p < 0.01 vs. WT-DOX mice.